20 Berkeley Square
About Arix BioscienceArix Bioscience is a healthcare and life science company that drives value in private and public companies through operational and strategic support and direction as well as patient capital.
The creation of renowned figures in the healthcare and life science sectors, Arix Bioscience is headquartered in London and has offices in New York.
CEO: Dr. Joe Anderson
Chairman: Jonathan Peacock
Deputy Chairman: Professor Sir Christopher Evans
CFO: James Rawlingson
25 articles with Arix Bioscience
Arix Bioscience plc (LSE:ARIX) ("Arix"), a global venture capital company investing in and building breakthrough biotech companies, today announces that Christian Schetter, PhD, currently Entrepreneur in Residence at Arix, has been appointed as a Managing Director.
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
Quench Bio, a company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, announced the completion of a $50 million Series A financing led by RA Capital Management, with participation from new Investor Abbvie Ventures.
Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences, today announces its annual results for the year ended 31 December 2018.
Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, will announce its annual results for the period ended 31 December 2018 on Thursday, 28 March 2019.
Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces it has invested in new portfolio company Imara, Inc. (“Imara”), a company dedicated to developing novel therapeutics for chronic treatment of Sickle Cell Disease (“SCD”) and other hemoglobinopathies.
2/22/2019Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more.
Arix Bioscience plc (LSE:ARIX) ("Arix" or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that Chief Investment Officer, Joe Anderson, has been reappointed as Chief Executive Officer and will re-join the Arix Board.
Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today announces the appointment of Dr Christian Schetter as Entrepreneur in Residence (EIR)
Arix Bioscience plc is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).
Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio1 to 15 companies
VelosBio raised $58 million in a Series A financing. It was co-led by Arix Bioscience, which committed $11 million, which will give them an 11.2 percent ownership stake, and Sofinnova Ventures.
9/17/2018Let's take a look at some of the professionals moving to transition the pharma and biotech world this past week.
Arix Bioscience plc today announced that industry veteran Arthur Pappas has been appointed as Non-Executive Director to the Arix Board of Directors.
Changes announced to executive team to accelerate growth and strategy
Arix Bioscience plc (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announces that it has acquired an 11 per cent interest in Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.
Evotec Forms Academic Bridge 'LAB591' with Arix Bioscience and Fred Hutchinson Cancer Research Center
Initial term of LAB591 is five years.
Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialise Innovative Therapies
Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialize Innovative Therapies